ALTME.PA AI Price Prediction

Negative EPS and a negative P/E ratio indicate that TME Pharma is currently loss‑making, with no clear evidence of near‑term profitability. The valuation is therefore driven more by speculative expectations than by earnings support.

• EPS of -0.03 and a P/E of -2.63 confirm the company is not generating positive net income.
• A negative P/E suggests investors cannot rely on traditional earnings-based valuation metrics, increasing risk and volatility.
• Without positive earnings or visibility on improving profitability ratios, the equity story is fundamentally weak and highly dependent on future milestones or financing.

Alternative data suggest very limited commercial traction and investor interest. Web traffic, hiring activity, and social media growth are all extremely low, pointing to a small operational footprint and weak external engagement.

• Estimated web traffic of only ~229 visitors per month indicates minimal online visibility and weak inbound interest from patients, partners, or investors.
• Zero current job openings and no month‑over‑month growth imply no visible expansion or scaling of operations, which is atypical for a company in a strong growth phase.
• Social media presence is very small (817 Twitter/X followers and 28 YouTube subscribers) with negligible growth over 90 days, suggesting limited market awareness and weak investor‑relations reach.

Overall, TME Pharma appears fundamentally weak, with negative earnings, no clear profitability path, and very limited alternative‑data evidence of growth or engagement. The recent 1‑month price increase is not yet supported by strong fundamentals or robust external signals, leaving the risk/reward profile skewed to the downside.

• Loss‑making financial profile and negative P/E make the stock highly speculative and sensitive to funding and pipeline news rather than earnings strength.
• Flat long‑term technical trend around the 200‑day moving average, combined with weak web, hiring, and social media signals, supports a bearish overall stance despite short‑term price gains.